This can in case of ER/HER4 double positive BC potentially be accomplished by a dual targeting of both receptor types using for instance tamoxifen and an HER4 specific antibody with anti-tumorigenic activity [31, 32]. The gene discussed is ERBB4; the disease is breast cancer.